Active, Not Recruiting
A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting - CA180-616
Updated: 24 December, 2019 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: - Patients aged greater than or equal to 18 years - Patients diagnosed with CP-CML - Patients who started dasatinib within the last month before inclusion, or on the day of inclusion or within the month after inclusion Exclusion Criteria: - Patients participating in an ongoing interventional trial - Patients diagnosed with AP-CML (accelerated phase) or BP-CML (blast phase)
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information